Therma Bright (TSE:THRM)
:THRM
Want to see TSE:THRM full AI Analyst Report?
THRM Stock Chart & Stats
C$0.06
>-C$0.01(-12.50%)
At close: 4:00 PM EST
C$0.06
>-C$0.01(-12.50%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.16
Previous CloseN/A
Volume10.00K
Average Volume (3M)50.06K
Market Cap
C$3.36M
Enterprise ValueC$3.22M
Total Cash (Recent Filing)C$36.19K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding58,002,876
10 Day Avg. Volume51,225
30 Day Avg. Volume50,057
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.51
Price to Sales (P/S)48.92
P/FCF Ratio-26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported DebtVery low reported debt materially reduces near-term leverage and interest burden for a small med-tech developer. This structural advantage lengthens runway versus highly levered peers, giving management scope to prioritize R&D and commercialization before needing costly debt refinancings.
Improving Operating Cash FlowMaterial improvement in operating cash outflows indicates the company has tightened spending or improved collections, a structural step toward sustainable operations. If maintained, this lower burn rate extends time to self-fund product commercialization and reduces immediate funding pressure.
Gross Margin RecoveryReturn to positive gross margins reflects better unit economics or cost control in product manufacturing/pricing. Sustained mid-teens to low-20s gross margin levels would support eventual operating leverage as revenue stabilizes, making long-term profitability more attainable.
Bears Say
Negative Shareholders' EquityMeaningfully negative equity signals accumulated losses that weaken the balance sheet and restrict financing options. Over months this reduces covenant flexibility, can complicate partnerships or supplier terms, and increases reliance on dilutive equity or nontraditional financing to sustain operations.
Persistent Cash BurnOngoing negative free cash flow implies the business cannot self-fund R&D, regulatory work, or commercialization. Persisting burn forces repeated external funding, raising dilution risk or insolvency if capital access tightens, and constrains long-term investment in competitive positioning.
Declining, Volatile Revenue & Deep LossesA falling and inconsistent top line combined with very large negative margins undermines the company’s ability to scale. Structural revenue weakness reduces the payoff from margin improvements and makes sustaining commercialization, regulatory milestones, and customer adoption materially harder without sizable funding.
Therma Bright News
THRM FAQ
What was Therma Bright’s price range in the past 12 months?
Therma Bright lowest stock price was C$0.04 and its highest was C$0.16 in the past 12 months.
What is Therma Bright’s market cap?
Therma Bright’s market cap is C$3.36M.
When is Therma Bright’s upcoming earnings report date?
Therma Bright’s upcoming earnings report date is Jul 01, 2026 which is in 42 days.
How were Therma Bright’s earnings last quarter?
Therma Bright released its earnings results on Apr 07, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Therma Bright overvalued?
According to Wall Street analysts Therma Bright’s price is currently Overvalued.
Does Therma Bright pay dividends?
Therma Bright does not currently pay dividends.
What is Therma Bright’s EPS estimate?
Therma Bright’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Therma Bright have?
Therma Bright has 58,002,876 shares outstanding.
What happened to Therma Bright’s price movement after its last earnings report?
Therma Bright reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Therma Bright?
Currently, no hedge funds are holding shares in TSE:THRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Therma Bright
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
Technical Analysis
Imagin Medical
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―
Options Prices
Currently, No data available
---